AKESO News

康方生物：自願公告 - PFS HR 0.51, mPFS 11.14個月依沃西單藥對比帕博利珠1L治療PD-L1表達陽性NSCLC (AK112-303/HARMONI -2) III期數據重磅發表於2024 WCLC

Sep 8 18:32 ET

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 August 2024

Sep 3 05:00 ET

AKESO: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024

Aug 28 09:56 ET

AKESO: DATE OF BOARD MEETING

Aug 16 06:00 ET

AKESO: VOLUNTARY ANNOUNCEMENT - AK112-303/HARMONI-2 WAS ACCEPTED AS LBA OF 2024 WCLCPRESIDENTIAL SYMPOSIUM ORAL PRESENTATION

Aug 11 19:42 ET

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 July 2024

Aug 5 04:05 ET

AKESO: VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTED THE SUPPLEMENTAL NEW DRUG APPLICATIONFOR IVONESCIMAB (PD-1/VEGF) MONOTHERAPY AS FIRST-LINETREATMENT FOR NSCLC WITH POSITIVE PD-L1 EXPRESSION

Jul 30 08:03 ET

AKESO: APPOINTMENT OF CHIEF FINANCIAL OFFICER

Jul 21 20:15 ET

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 June 2024

Jul 5 00:36 ET

AKESO: LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

Jul 1 06:28 ET

AKESO: CHANGE OF DIRECTORS

Jul 1 06:26 ET

AKESO: POLL RESULTS OF THE ANNUAL GENERAL MEETINGHELD ON SUNDAY, JUNE 30, 2024

Jul 1 06:21 ET

AKESO: FORM OF PROXY FOR THE ANNUAL GENERAL MEETINGTO BE HELD ON SUNDAY, JUNE 30, 2024

Jun 6 04:43 ET

AKESO: NOTICE OF ANNUAL GENERAL MEETING

Jun 6 04:42 ET

AKESO: PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF RETIRING DIRECTORS; PROPOSED AMENDMENTS TO THE 2021 RSU SCHEME; PROPOSED AMENDMENTS TO THE SHARE OPTION SCHEME; PROPOSED RE-APPOINTMENT OF AUDITORS; AND NO

Jun 6 04:41 ET

AKESO: (I) PROPOSED AMENDMENTS TO THE 2021 RSU SCHEME ANDTHE SHARE OPTION SCHEME; AND (II) TERMINATIONOF THE PRE-IPO RSU SCHEME

Jun 5 10:38 ET

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 May 2024

Jun 5 04:55 ET

AKESO: VOLUNTARY ANNOUNCEMENT - AMENDMENT TO THE LICENSE AGREEMENT FORIVONESCIMAB (PD-1/VEGF) WITHSUMMIT THERAPEUTICS INC.

Jun 3 07:32 ET

AKESO: VOLUNTARY ANNOUNCEMENT - AK112-303 REACHED PRIMARY ENDPOINT OF PFS SUPERIORITYIVONESCIMAB DEMONSTRATED A STATISTICALLY SIGNIFICANTAND CLINICALLY MEANINGFUL SUPERIORITYAS FIRST LINE MONOTHERAPY FOR PD-L1+ NSCLCVERSUS PEMBROLIZUMAB, HAZARD RATIO SIGNIFIC

May 30 18:33 ET

AKESO: VOLUNTARY ANNOUNCEMENT(IVONESCIMAB INJECTION) OBTAINEDNMPA'S MARKETING APPROVAL IN CHINA

May 24 00:25 ET